PharmaEssentia (6446) Q4 2024 earnings summary

Executive summary

• Achieved a significant turnaround with net income of $2,965,503 thousand for 2024, compared to a net loss of $623,835 thousand in 2023.

• Revenue more than doubled year-over-year to $3,501,966 thousand, driven by strong medicine product sales, especially in the US market.

• Comprehensive income reached $3,262,589 thousand, reflecting robust operational and financial performance.

Financial highlights

• Operating revenue rose to $3,501,966 thousand in 2024 from $1,545,209 thousand in 2023.

• Gross profit from operations increased to $2,746,361 thousand, with a gross margin of 78%.

• Operating expenses totaled $3,093,194 thousand, with R&D expenses at $2,356,813 thousand.

• Earnings per share improved to $8.96 basic and $8.88 diluted, up from $(1.93) in 2023.

• Cash and cash equivalents at year-end were $12,772,611 thousand.

Outlook and guidance

• The company expects continued revenue growth from medicine product sales, with unsatisfied performance obligations of $229 thousand to be recognized by end of 2025.

• Ongoing expansion of manufacturing capacity and clinical trial pipeline to support future growth.